Phocas Financial’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Phocas Financial's ACAD Position: Q3 2026 in Review
Phocas Financial sold out of Acadia Pharmaceuticals (ACAD) in Q3 2026, closing a stake of 77,245 shares — an estimated $1.95M sold.
Phocas Financial first reported a position in ACAD in Q3 2023 and held it in 9 quarters. The position peaked at $2.78M in Q4 2025. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Phocas Financial reported no remaining Acadia Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Phocas Financial sold 77,245 Acadia Pharmaceuticals shares in Q3 2026, an estimated $1.95M.
- Phocas Financial first reported a position in Acadia Pharmaceuticals in Q3 2023 and held it in 9 quarters.
- Phocas Financial's Acadia Pharmaceuticals position peaked at $2.78M in Q4 2025.
- 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Phocas Financial's 13F filing for Q3 2026.